SyntheticMR’s SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

SyntheticMR announced today that their quantitative imaging software solution for knee and spine imaging, SyMRI MSK, has received regulatory approval in Brazil and can now be sold and distributed in this market. 

The SyMRI MSK package supports a fast-imaging workflow and enhanced capabilities to view tissue properties on an absolute scale in a short scan time. 

Additionally, MSK allows the radiologists to deliver the most common contrast weighted images, quantitative R1, R2 and proton density maps for advanced tissue analysis with a single sequence. 

Learn more about SyMRI MSK and what this exciting expansion has to offer! 

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com or Hege Nåbo, CMO, +46 70 327 24 21 hege.nabo@syntheticmr.com. 

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI^®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.